Collaborative Innovation in Biomedicine
June 22, 2009 • 8h30 - 19h
Marriott at Metro Center Hotel, Washington DC
This conference will cover key issues, challenges and best practices for Collaborative Innovation in Biomedicine, including:
- How to Create and Manage Consortia for Success
- Data Contribution, Results Sharing and Enhancement Solutions
- IP Issues for Consortia-Generated Knowledge
- Moving from Pre-Competitive Collaboration Back into Competitive Programs
- Case Studies of Leading Consortia
Including Pharmaceutical Company Perspectives on Collaborative Innovation Consortia from:
Merck & Co. | Eli Lilly and Company | GlaxoSmithKline | Pfizer | Johnson & Johnson
Conference Program Advisors:
- Dr. William B. Mattes, Director, Toxicology, Critical Path Institute
- Dr. Elizabeth G. Walker, Assistant Director, Toxicology, Predictive Safety Testing Consortium, Critical Path Institute
- Dr. Jackie Hunter, Senior Vice President, Science Environment Development, GlaxoSmithKline
- Dr. Susie M. Stephens, I.T. Manager / Principal Research Scientist, Eli Lilly, Discovery I.T. Department, Eli Lilly and Company
As the pharmaceutical industry moves closer to what has been described as a “Revenue Cliff”, as a number of key patents expire on major drugs, at the same time as the industry confronts the additional challenges of a dramatic decline in pipeline productivity, declining availability of R&D resources, and increased regulatory and business practice pressures, new models for drug discovery and development become critical to the industry’s future. Pre-competitive consortia are becoming an important alternative model for accelerating drug discovery and development, while sharing resources and costs. Current consortia have produced some notable successes and provide a valuable approach for better understanding where the best opportunities for collaboration may exist, what strategies to employ and how to win support for such efforts.
This important program will explore pre-competitive, multiple party, consortia-based collaborations in drug discovery and development, examining key questions and issues, including:
- How should equal partners be brought together?
- What if the partners are not equal in size or contribution?
- What is the impact of creating and communicating a compelling Vision and Mission for such consortia?
- What are the Best Solutions for data contribution and sharing?
- What Organizational Models work most effectively in which situations?
- What are the current Best Practices for how such consortia should be organized and managed?
- What New Models are proven to generate higher levels of IP?
- How can IP be shared effectively, while being protected?
- How to move from Collaborative Consortia back into competitive programs.
This leading-edge conference will feature key speakers from pharmaceutical companies and non-profit organizations, with first-hand experience in setting up and managing successful consortia, as we explore the most important new models, key issues, challenges and best practices of Collaborative Innovation in Biomedicine.
Case studies of emerging consortia-based models and best practices will be featured from such organizations and consortia as:
- The Dundee Kinase Consortium
- Innovative Medicines Initiative (IMI)
- The Critical Path Institute
- The Serious Adverse Events Consortium
- The Biomarkers Consortium
- The European Medicines Agency (EMEA)
- Drug Safety and Toxicology Consortia
- Drug Safety Executive Council (DSEC)
- Health Commons
- ILSI Health and Environmental Sciences Institute (HESI)
- The Predictive Safety Testing Consortium (PSTC)
We look forward to seeing you at this important conference.
President, Cambridge Healthtech Institute
Alliance Director and Senior Conference Producer,
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
For information on sponsorships and exhibits, please contact:
Manager, Business Development,
Cambridge Healthtech Institute
This content has been updated on August 16, 2015 at 22:56.